NIKKEI 225
38,703.51 +213.34 (+0.55%) HANG SENG
18,476.80 +51.84 (+0.28%) CRUDE OIL
75.54 +1.47 (+1.98%) GOLD FUTURES
2,389.10 +13.60 (+0.57%) DOW
38,793.19 -14.14 (-0.04%) Bitcoin GBP
55,485.77 -268.73 (-0.48%)
BMEA Oct 2024 17.500 put
| Previous close | 5.80 |
| Open | 5.80 |
| Bid | 6.30 |
| Ask | 6.60 |
| Strike | 17.50 |
| Expiry date | 2024-10-18 |
| Day's range | 5.80 - 5.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireBiomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on June 1, 2024, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of
- GlobeNewswire
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cellsREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose exp
Simply Wall St.Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
